This is a summary of the European public assessment report (EPAR) for Buccolam. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Buccolam.
Buccolam : EPAR - Summary for the public (PDF/50.45 KB)
First published: 19/09/2011
Last updated: 19/09/2011
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Laboratorios Lesvi S.L.
|Date of issue of marketing authorisation valid throughout the European Union||
Avinguda Barcelona 69
31/10/2022 Buccolam - EMEA/H/C/002267 - IB/0056
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents (from three months to less than 18 years).
Buccolam must only be used by parents / carers where the patient has been diagnosed to have epilepsy.
For infants between three and six months of age, treatment should be in a hospital setting where monitoring is possible and resuscitation equipment is available.